FOR IMMEDIATE RELEASE
September 1, 2011All quotes can be attributed to Martin S. Levine, DO, President
of the American Osteopathic Association
(Washington, DC)— The American Osteopathic Association (AOA) applauds the broad agreement reached by key stakeholders that promotes reauthorization of the Prescription Drug User Fee Act (PDUFA).
We appreciate the work of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Food and Drug Administration (FDA) in this effort. The just announced agreement between the pharmaceutical industry and FDA regarding technical specifications of PDUFA paves a path forward – a path toward a safe pharmaceutical market, along with the introduction of new and improved medicines.
This agreement will benefit physicians and their patients alike as both clinical efficacy and patient safety have been the driving force behind the agreement. We applaud the leadership PhRMA and the FDA have demonstrated in this effort. The osteopathic profession looks forward to working with Congress on the reauthorization of the Prescription Drug User Fee Act.
About the American Osteopathic Association
The American Osteopathic Association proudly represents more than 78,000 osteopathic physicians (DOs) practicing in 31 specialties and subspecialties, promotes public health, encourages scientific research, serves as the primary certifying body for DOs, is the accrediting agency for osteopathic medical colleges; and has federal authority to accredit hospitals and other health care facilities. More information on DOs/osteopathic medicine can be found at www.osteopathic.org.
###
Media Contact:
Leann Fox
Director of Washington Advocacy and Communications
(202) 414-0144 (Office)
lfox@osteopathic.org